Clinical Trials Logo

Tophaceous Gout clinical trials

View clinical trials related to Tophaceous Gout.

Filter by:
  • None
  • Page 1

NCT ID: NCT06186219 Enrolling by invitation - Tophaceous Gout Clinical Trials

Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout

Start date: April 10, 2024
Phase: Phase 1
Study type: Interventional

This safety and feasibility, open-label study of up to 9 subjects will examine a group of subjects with poorly controlled tophaceous gout (intolerant to or ineffective oral urate lowering agents and loss of prior Pegloticase response) pre-treated with Rituximab to recapture response to Methotrexate-Pegloticase.

NCT ID: NCT03965676 Recruiting - Tophaceous Gout Clinical Trials

Evolution of Tophus and Erosions of Hands and Feet at DECT

TOPHERO-CT
Start date: July 24, 2019
Phase: N/A
Study type: Interventional

The main objective is to evaluate the decrease in crystalline volume of the target tophus using Dual-Energy Computed Tomography (DECT), after 6 months +/- 1 month of urate-lowering therapy with target uricemia. Study hypothesis - The dynamics of tophus resolution with urate-lowering therapy is poorly understood. - It is variable according to the location of the tophus, peri articular / intratendinous, but also probably at the feet / hands, the initial overall volume of the tophus, the initial crystal charge of the tophus. Knowledge of prognostic factors for tophus resolution will help determine the best target for treatment follow-up for each patient. - Erosions are the consequence of tophus. Tophus resolution could be associated with repair of erosions and stabilization of joint destruction.

NCT ID: NCT01510769 Completed - Tophaceous Gout Clinical Trials

Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat

CRYSTAL
Start date: January 2012
Phase: Phase 3
Study type: Interventional

This study will compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with febuxostat to febuxostat alone in patients with tophaceaous gout.